MOUNTAIN VIEW, Calif. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating

- Multi-year, Multi-target Agreement Intended to Expedite Discovery of Novel IgM Antibodies - VANCOUVER, British Columbia and MOUNTAIN VIEW, Calif. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- AbCellera and IGM Biosciences, Inc. (Nasdaq: IGMS), announced today that they have entered into a multi-year,

MOUNTAIN VIEW, Calif. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will present at four upcoming investor

­   - IND for IGM-8444 for treatment of patients with solid cancers cleared by FDA - - Kathy Miller , Ph.D., appointed Vice President, Antibody Discovery - - Phase I clinical trial of IGM-2323 continues - MOUNTAIN VIEW, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc.

MOUNTAIN VIEW, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 2020 Wedbush PacGrow

MOUNTAIN VIEW, Calif. , May 28, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will present at the Jefferies 2020

MOUNTAIN VIEW, Calif. , May 12, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will present at the 2020 RBC Capital

- Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in the second half of 2020 - - IND filing for IGM-8444 planned in 2020 - - Collaboration with Atreca and BeiGene to discover, develop and manufacture novel antibody treatment for COVID-19 announced

- Companies to utilize proprietary platforms to discover, develop, and manufacture potential  therapeutic antibodies to combat ongoing COVID-19 pandemic - SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass. and BEIJING, China and MOUNTAIN VIEW, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc.

MOUNTAIN VIEW, Calif. , April 03, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in a panel discussion